|
EP1355666B1
(en)
|
2000-12-22 |
2012-06-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Use of repulsive guidance molecule (RGM) and its modulators
|
|
US8906864B2
(en)
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
|
EP2033971A1
(de)
*
|
2007-09-06 |
2009-03-11 |
Abbott GmbH & Co. KG |
Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
|
|
WO2009095478A1
(en)
|
2008-01-31 |
2009-08-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
RS54233B1
(sr)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc. |
Kompozicije pd-1 antagonista i postupci za njihovu primenu
|
|
MX2012006560A
(es)
*
|
2009-12-08 |
2012-10-05 |
Abbott Gmbh & Co Kg |
Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
|
|
CN102675460B
(zh)
*
|
2011-02-28 |
2015-08-19 |
珠海市丽珠单抗生物技术有限公司 |
抗肿瘤坏死因子α的人源化抗体
|
|
JP6072771B2
(ja)
*
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
JP6240600B2
(ja)
*
|
2011-07-24 |
2017-11-29 |
キュアテク リミテッド |
ヒト化免疫モノクローナル抗体の変異体
|
|
EA026924B1
(ru)
|
2011-08-01 |
2017-05-31 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
|
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
|
PE20190907A1
(es)
|
2012-01-27 |
2019-06-26 |
AbbVie Deutschland GmbH and Co KG |
Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
|
|
RU2689760C2
(ru)
|
2012-05-31 |
2019-05-30 |
Дженентек, Инк. |
Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
|
|
US9758591B2
(en)
|
2012-08-24 |
2017-09-12 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
|
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
|
HK1214831A1
(zh)
|
2012-11-05 |
2016-08-05 |
Foundation Medicine, Inc. |
新型融合分子及其应用
|
|
WO2014089113A1
(en)
|
2012-12-03 |
2014-06-12 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
HK1216647A1
(zh)
|
2012-12-12 |
2016-11-25 |
Vasculox Inc. |
治疗性cd47抗体
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
ES2814962T3
(es)
|
2013-02-20 |
2021-03-29 |
Novartis Ag |
Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
|
|
PL2958943T3
(pl)
|
2013-02-20 |
2020-04-30 |
The Trustees Of The University Of Pennsylvania |
Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
|
|
DK2964638T3
(en)
|
2013-03-06 |
2017-10-30 |
Astrazeneca Ab |
QUINAZOLIN INHIBITORS TO ACTIVATE MUTANEOUS FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
AU2014251087B2
(en)
|
2013-04-09 |
2019-05-02 |
Lixte Biotechnology, Inc. |
Formulations of oxabicycloheptanes and oxabicycloheptenes
|
|
AU2014290069B2
(en)
|
2013-07-16 |
2019-01-03 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
|
|
CN105612175B
(zh)
|
2013-08-08 |
2023-05-09 |
赛腾制药 |
基于IL-15和IL-15Rαsushi结构域的调节因子
|
|
PT3030262T
(pt)
|
2013-08-08 |
2019-12-11 |
Inst Gustave Roussy Igr |
Composição farmacêutica de associação
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
|
US9580504B1
(en)
*
|
2013-11-07 |
2017-02-28 |
Curetech Ltd. |
Pidilizumab monoclonal antibody therapy following stem cell transplantation
|
|
CA2929181A1
(en)
|
2013-11-13 |
2015-05-21 |
Novartis Ag |
Mtor inhibitors for enhancing the immune response
|
|
US20150140125A1
(en)
*
|
2013-11-19 |
2015-05-21 |
Life Plus, LLC |
Synergistic cancer therapy drug combinations
|
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
MX2016007885A
(es)
|
2013-12-17 |
2017-01-11 |
Genentech Inc |
Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
|
|
NZ760065A
(en)
*
|
2013-12-17 |
2022-12-23 |
Genentech Inc |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
ES2716685T3
(es)
|
2014-01-24 |
2019-06-14 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo para PD-1 y usos de las mismas
|
|
DK3099717T3
(da)
|
2014-01-31 |
2019-07-01 |
Novartis Ag |
Antistofmolekyler med tim-3 og anvendelser deraf
|
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
|
KR20170003912A
(ko)
|
2014-03-19 |
2017-01-10 |
매카이 메디컬 파운데이션 더 프레즈비티리언 처치 인 타이완 매카이 메모리얼 호스피탈 |
면역원성 당펩타이드에 대한 항체, 이를 포함하는 조성물 및 이의 용도
|
|
WO2015148379A1
(en)
|
2014-03-24 |
2015-10-01 |
Novartis Ag |
Monobactam organic compounds for the treatment of bacterial infections
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
HRP20192285T1
(hr)
|
2014-03-31 |
2020-03-06 |
F. Hoffmann - La Roche Ag |
Anti-ox40 protutijela i postupci uporabe
|
|
SI3888674T1
(sl)
|
2014-04-07 |
2024-08-30 |
Novartis Ag |
Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
|
|
EP3129509B1
(en)
|
2014-04-10 |
2020-06-17 |
Bio-Marcare Technologies Ltd. |
Methods and kits for identifying pre-cancerous colorectal polyps and colorectal cancer
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
AU2015287227B2
(en)
|
2014-07-10 |
2021-02-18 |
Universitat Zurich |
Immune-stimulating monoclonal antibodies against human interleukin-2
|
|
BR112017000497B1
(pt)
|
2014-07-11 |
2023-12-26 |
Ventana Medical Systems, Inc |
Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
|
|
EP3563870A1
(en)
|
2014-07-15 |
2019-11-06 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
CN107001316A
(zh)
|
2014-08-06 |
2017-08-01 |
诺华股份有限公司 |
作为抗菌剂的喹诺酮衍生物
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
RU2020117196A
(ru)
|
2014-08-19 |
2020-10-15 |
Новартис Аг |
Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
HRP20201656T1
(hr)
|
2014-09-16 |
2021-03-05 |
Innate Pharma |
Neutralizacija inhibitornih putova u limfocitima
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
EP3662903A3
(en)
|
2014-10-03 |
2020-10-14 |
Novartis AG |
Combination therapies
|
|
CA2963935A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
KR102536786B1
(ko)
|
2014-10-10 |
2023-05-26 |
이나뜨 파르마 에스.에이. |
Ｃｄ７３ 차단
|
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
|
AU2015343337A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Assays for detecting T cell immune subsets and methods of use thereof
|
|
CN107109484B
(zh)
|
2014-11-03 |
2021-12-14 |
豪夫迈·罗氏有限公司 |
用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
|
|
US20170313775A1
(en)
|
2014-11-13 |
2017-11-02 |
The Johns Hopkins University |
Checkpoint Blockade and Microsatellite Instability
|
|
TW201625692A
(zh)
|
2014-11-14 |
2016-07-16 |
諾華公司 |
抗體藥物結合物
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
RU2753902C2
(ru)
|
2014-11-20 |
2021-08-24 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
|
|
CN107531690B
(zh)
|
2014-11-27 |
2020-11-06 |
基因泰克公司 |
用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
PT3227339T
(pt)
|
2014-12-05 |
2022-01-14 |
Eureka Therapeutics Inc |
Recetores de antigénio quiméricos que têm como alvo o recetor 4 acoplado a proteína g e utilizações dos mesmos
|
|
CN107206088A
(zh)
|
2014-12-05 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
|
|
KR20230159637A
(ko)
|
2014-12-05 |
2023-11-21 |
메모리얼 슬로안 케터링 캔서 센터 |
G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
|
|
HRP20192009T1
(hr)
|
2014-12-16 |
2020-02-07 |
Novartis Ag |
Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
EP3250250A4
(en)
|
2015-01-30 |
2019-05-22 |
President and Fellows of Harvard College |
PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP3259288A1
(en)
|
2015-02-20 |
2017-12-27 |
Innate Pharma |
Cd73 blockade
|
|
AR103726A1
(es)
*
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
|
CA2979215A1
(en)
|
2015-03-10 |
2016-09-15 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
|
EP3067062A1
(en)
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
|
|
EP3280795B1
(en)
|
2015-04-07 |
2021-03-24 |
Novartis AG |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
MX2017012805A
(es)
|
2015-04-07 |
2018-04-11 |
Genentech Inc |
Complejo de unión a antígenos con actividad agonista y métodos de uso.
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
PL3291679T3
(pl)
|
2015-05-06 |
2022-04-25 |
Snipr Technologies Limited |
Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty
|
|
EP3294770B2
(en)
|
2015-05-12 |
2024-03-20 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
|
CN104987421A
(zh)
*
|
2015-05-13 |
2015-10-21 |
北京比洋生物技术有限公司 |
抗ctla-4和pd-1的双重可变结构域免疫球蛋白
|
|
ES2889906T3
(es)
|
2015-05-21 |
2022-01-14 |
Harpoon Therapeutics Inc |
Proteínas de unión triespecíficas y usos médicos
|
|
SI3303394T1
(sl)
|
2015-05-29 |
2020-10-30 |
Agenus Inc. |
Protitelesa proti-CTLA-4 in postopki njihove uporabe
|
|
KR20250151554A
(ko)
|
2015-05-29 |
2025-10-21 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
EP3303399A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies
|
|
IL256080B2
(en)
|
2015-06-17 |
2025-06-01 |
Genentech Inc |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
|
KR20180034426A
(ko)
|
2015-07-29 |
2018-04-04 |
노파르티스 아게 |
암의 치료에서의 항 pd-1 및 항 m-csf 항체의 조합 용도
|
|
EP3328407A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination of pd-1 antagonist with an egfr inhibitor
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
HUE055207T2
(hu)
|
2015-07-30 |
2021-11-29 |
Macrogenics Inc |
PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
CN108349985A
(zh)
|
2015-09-14 |
2018-07-31 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
EP3349787A4
(en)
|
2015-09-18 |
2019-03-27 |
Arch Oncology, Inc. |
THERAPEUTIC CD47 ANTIBODIES
|
|
HK1251158A1
(zh)
|
2015-09-29 |
2019-01-25 |
细胞基因公司 |
Pd-1结合蛋白及其使用方法
|
|
JP2018529719A
(ja)
|
2015-09-30 |
2018-10-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
|
|
SMT202100506T1
(it)
|
2015-10-02 |
2021-11-12 |
Hoffmann La Roche |
Anticorpi bispecifici specifici per pd1 e tim3
|
|
WO2017064043A1
(en)
|
2015-10-12 |
2017-04-20 |
Innate Pharma |
Cd73 blocking agents
|
|
EP3362074B1
(en)
|
2015-10-16 |
2023-08-09 |
President and Fellows of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
|
CN108430515B
(zh)
|
2015-10-29 |
2021-11-12 |
诺华股份有限公司 |
包含toll-样受体激动剂的抗体缀合物
|
|
LT3370733T
(lt)
|
2015-11-02 |
2021-10-25 |
Board Of Regents, The University Of Texas System |
Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai
|
|
EP3371311B1
(en)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
KR20180104597A
(ko)
|
2015-11-07 |
2018-09-21 |
멀티비르 인코포레이티드 |
암 치료를 위한 종양 억제 유전자 요법 및 면역관문 봉쇄를 포함하는 조성물
|
|
CN121154828A
(zh)
|
2015-11-19 |
2025-12-19 |
豪夫迈·罗氏有限公司 |
使用b-raf抑制剂和免疫检查点抑制剂治疗癌症的方法
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
ES2901794T3
(es)
|
2015-12-09 |
2022-03-23 |
Hoffmann La Roche |
Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
|
|
EA201891178A1
(ru)
|
2015-12-14 |
2019-01-31 |
Макродженикс, Инк. |
Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
|
US11433136B2
(en)
|
2015-12-18 |
2022-09-06 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
MA44146B1
(fr)
|
2015-12-22 |
2023-10-31 |
Regeneron Pharma |
Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
|
|
US11413340B2
(en)
|
2015-12-22 |
2022-08-16 |
Novartis Ag |
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
|
|
RU2625598C2
(ru)
*
|
2015-12-31 |
2017-07-17 |
Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации |
Способ лечения больных локальным раком простаты, относящихся к группе высокого риска прогрессирования заболевания
|
|
AR107303A1
(es)
|
2016-01-08 |
2018-04-18 |
Hoffmann La Roche |
Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
|
|
BR112018014150A2
(en)
|
2016-01-11 |
2018-12-11 |
Novartis Ag |
immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
|
|
PL3405495T3
(pl)
|
2016-01-21 |
2021-10-11 |
Innate Pharma |
Neutralizacja szlaków inhibitorowych w limfocytach
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
DK3411398T3
(da)
|
2016-02-05 |
2024-06-24 |
Orionis Biosciences BV |
Målrettede terapeutiske midler og anvendelse heraf
|
|
AU2017219216B2
(en)
|
2016-02-19 |
2019-12-19 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
|
WO2017151517A1
(en)
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
WO2017149515A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
AU2017230850B2
(en)
|
2016-03-08 |
2024-04-18 |
Innate Pharma |
Siglec neutralizing antibodies
|
|
MX2018010546A
(es)
|
2016-03-15 |
2019-02-20 |
Chugai Pharmaceutical Co Ltd |
Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
|
|
WO2017165412A2
(en)
|
2016-03-21 |
2017-09-28 |
Dana-Farber Cancer Institute, Inc. |
T-cell exhaustion state-specific gene expression regulators and uses thereof
|
|
FI3433257T3
(fi)
|
2016-03-24 |
2024-01-08 |
Novartis Ag |
Alkynyylinukleosidianalogeja ihmisen rinoviruksen estäjinä
|
|
JP7208010B2
(ja)
|
2016-03-29 |
2023-01-18 |
ユニバーシティ オブ サザン カリフォルニア |
癌を標的とするキメラ抗原受容体
|
|
EP3436829A1
(en)
|
2016-03-30 |
2019-02-06 |
Centre Léon-Bérard |
Lymphocytes expressing cd73 in cancerous patient dictates therapy
|
|
WO2017173091A1
(en)
|
2016-03-30 |
2017-10-05 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
|
|
EP3225253A1
(en)
|
2016-04-01 |
2017-10-04 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
|
|
AU2017250191A1
(en)
|
2016-04-13 |
2018-11-08 |
Orimabs Ltd. |
Anti-PSMA antibodies and use thereof
|
|
US20190218515A1
(en)
|
2016-04-13 |
2019-07-18 |
Vivia Biotech, S.L. |
Ex vivo bite-activated t cells
|
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
CN114634569B
(zh)
*
|
2016-04-15 |
2024-08-20 |
达特茅斯大学理事会 |
高亲和力b7-h6抗体和抗体片段
|
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
|
JP7131773B2
(ja)
|
2016-04-29 |
2022-09-06 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ホルモン受容体に関連する転写活性の標的尺度
|
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
JP7105200B2
(ja)
|
2016-05-13 |
2022-07-22 |
オリオニス バイオサイエンシズ ビーブイ |
標的突然変異体インターフェロン－ベータおよびその使用
|
|
EP3455245A2
(en)
|
2016-05-13 |
2019-03-20 |
Orionis Biosciences NV |
Therapeutic targeting of non-cellular structures
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
JP7160688B2
(ja)
|
2016-05-24 |
2022-10-25 |
ジェネンテック， インコーポレイテッド |
Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
|
CN109476663B
(zh)
|
2016-05-24 |
2021-11-09 |
基因泰克公司 |
用于治疗癌症的吡唑并吡啶衍生物
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
SG11201810656WA
(en)
|
2016-06-14 |
2018-12-28 |
Novartis Ag |
Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
CA3028718A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
MX2018016330A
(es)
|
2016-06-27 |
2020-02-17 |
Univ California |
Combinaciones para tratamiento del cáncer.
|
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
CN116769050A
(zh)
|
2016-07-20 |
2023-09-19 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
|
US20210369746A1
(en)
|
2016-08-01 |
2021-12-02 |
Molecular Templates, Inc. |
Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
|
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
BR112019002036A2
(pt)
|
2016-08-12 |
2019-05-14 |
Genentech Inc |
métodos de tratamento de um sujeito com câncer colorretal, kit para tratamento do câncer colorretal em um sujeito humano e combinação de fármacos para a terapia do câncer colorretal
|
|
MA45999A
(fr)
|
2016-08-22 |
2019-06-26 |
Arbutus Biopharma Corp |
Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
|
|
US11583516B2
(en)
|
2016-09-07 |
2023-02-21 |
Trustees Of Tufts College |
Dash inhibitors, and uses related thereto
|
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
|
MX2019002728A
(es)
|
2016-09-09 |
2019-08-16 |
Tg Therapeutics Inc |
Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres.
|
|
AU2017329024A1
(en)
|
2016-09-19 |
2019-03-21 |
Celgene Corporation |
Methods of treating immune disorders using pd-1 binding proteins
|
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
|
EP3515475B1
(en)
|
2016-09-21 |
2024-05-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
|
US11673971B2
(en)
|
2016-09-23 |
2023-06-13 |
Marengo Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
|
BR112019006041A2
(pt)
|
2016-09-27 |
2019-09-03 |
Board Of Regents, The University Of Texas System |
métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma
|
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
|
CN109862917A
(zh)
|
2016-09-29 |
2019-06-07 |
基因泰克公司 |
Mek抑制剂,pd-1轴抑制剂,和紫杉烷的组合疗法
|
|
IL265759B2
(en)
|
2016-10-06 |
2025-10-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
MY200337A
(en)
|
2016-10-07 |
2023-12-20 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
|
|
TW202436356A
(zh)
|
2016-10-11 |
2024-09-16 |
美商艾吉納斯公司 |
抗ｌａｇ－３抗體及其使用方法
|
|
WO2018071668A1
(en)
|
2016-10-12 |
2018-04-19 |
Board Of Regents, The University Of Texas System |
Methods and compositions for tusc2 immunotherapy
|
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
|
WO2018075960A1
(en)
|
2016-10-21 |
2018-04-26 |
Tioma Therapeutics, Inc. |
Therapeutic cd47 antibodies
|
|
ES2917000T3
(es)
|
2016-10-24 |
2022-07-06 |
Orionis Biosciences BV |
Interferón-gamma mutante diana y usos del mismo
|
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｍｉｃ抗体及び使用方法
|
|
US11124577B2
(en)
|
2016-11-02 |
2021-09-21 |
Engmab Sàrl |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
|
WO2018083087A2
(en)
|
2016-11-02 |
2018-05-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Binding proteins
|
|
EP3538112B1
(en)
|
2016-11-09 |
2026-02-25 |
Musc Foundation for Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
|
US11466094B2
(en)
|
2016-11-15 |
2022-10-11 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
US11446302B2
(en)
|
2016-11-17 |
2022-09-20 |
Board Of Regents, The University Of Texas System |
Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
WO2018102786A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
|
CN118634323A
(zh)
|
2016-12-07 |
2024-09-13 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
US11013802B2
(en)
|
2016-12-07 |
2021-05-25 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
NZ754522A
(en)
|
2016-12-08 |
2025-11-28 |
Lixte Biotechnology Inc |
Oxabicycloheptanes for modulation of immune response
|
|
CN110366562A
(zh)
|
2016-12-12 |
2019-10-22 |
豪夫迈·罗氏有限公司 |
使用抗pd-l1抗体和抗雄激素治疗癌症的方法
|
|
JP2020510624A
(ja)
|
2016-12-12 |
2020-04-09 |
マルチビア インコーポレイテッド |
がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
|
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
|
US12162932B2
(en)
|
2017-01-05 |
2024-12-10 |
Netris Pharma |
Combined treatment with Netrin-1 interfering drug and immune checkpoint inhibitors drugs
|
|
EP3568412A2
(en)
|
2017-01-13 |
2019-11-20 |
Agenus Inc. |
T cell receptors that bind to ny-eso-1 and methods of use thereof
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
US10906985B2
(en)
|
2017-02-06 |
2021-02-02 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
|
CA3052523A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences Nv |
Targeted chimeric proteins and uses thereof
|
|
US20200023071A1
(en)
|
2017-02-06 |
2020-01-23 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
US11693007B2
(en)
|
2017-02-24 |
2023-07-04 |
Board Of Regents, The University Of Texas System |
Assay for detection of early stage pancreatic cancer
|
|
BR112019017696A2
(pt)
|
2017-02-27 |
2020-04-07 |
Bristol Myers Squibb |
programa de dosagem para uma combinação de ceritinib e uma molécula de anticorpo anti-pd-1
|
|
PL3589754T3
(pl)
|
2017-03-01 |
2023-10-09 |
F. Hoffmann-La Roche Ag |
Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
|
|
US11179413B2
(en)
|
2017-03-06 |
2021-11-23 |
Novartis Ag |
Methods of treatment of cancer with reduced UBB expression
|
|
KR102584011B1
(ko)
|
2017-03-16 |
2023-09-27 |
이나뜨 파르마 에스.에이. |
암 치료를 위한 조성물 및 방법
|
|
WO2018175790A1
(en)
*
|
2017-03-22 |
2018-09-27 |
Arch Oncology, Inc. |
Combination therapy for the treatment of solid and hematological cancers
|
|
CN108623686A
(zh)
|
2017-03-25 |
2018-10-09 |
信达生物制药(苏州)有限公司 |
抗ox40抗体及其用途
|
|
CN110475567A
(zh)
|
2017-03-31 |
2019-11-19 |
勃林格殷格翰国际有限公司 |
抗癌组合疗法
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
KR20190121816A
(ko)
|
2017-04-03 |
2019-10-28 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
BR112019021032A2
(pt)
|
2017-04-05 |
2020-05-05 |
Boehringer Ingelheim International Gmbh |
terapia combinada anticâncer
|
|
PL3606955T3
(pl)
|
2017-04-05 |
2025-02-24 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
JP2020516638A
(ja)
|
2017-04-13 |
2020-06-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを処置する方法における使用のための、インターロイキン２イムノコンジュゲート、ｃｄ４０アゴニスト、および任意選択のｐｄ−１軸結合アンタゴニスト
|
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
EP3610042A1
(en)
|
2017-04-14 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
|
CA3058944A1
(en)
|
2017-04-19 |
2018-10-25 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
WO2018201047A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
US11021537B2
(en)
|
2017-05-01 |
2021-06-01 |
Agenus Inc. |
Anti-TIGIT antibodies and methods of use thereof
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
UY37718A
(es)
|
2017-05-05 |
2018-11-30 |
Novartis Ag |
2-quinolinonas triciclicas como agentes antibacteriales
|
|
BR112019023855B1
(pt)
|
2017-05-12 |
2021-11-30 |
Harpoon Therapeutics, Inc |
Proteínas de ligação à mesotelina
|
|
IL322309A
(en)
|
2017-05-24 |
2025-09-01 |
Novartis Ag |
IL2 antibody grafted proteins and methods of use in cancer treatment
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
EP3630834A1
(en)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
|
KR20200041834A
(ko)
|
2017-06-01 |
2020-04-22 |
젠코어 인코포레이티드 |
Cd123 및 cd3에 결합하는 이중특이성 항체
|
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
|
KR20200054160A
(ko)
|
2017-06-02 |
2020-05-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
|
|
CA3061053A1
(en)
|
2017-06-02 |
2018-12-06 |
Boehringer Ingelheim International Gmbh |
Anti-cancer combination therapy
|
|
CN121609797A
(zh)
|
2017-06-06 |
2026-03-06 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
|
WO2019006427A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
|
|
KR102677225B1
(ko)
|
2017-07-10 |
2024-06-24 |
이나뜨 파르마 에스.에이. |
Siglec-9 중화 항체
|
|
CN111492245A
(zh)
|
2017-07-21 |
2020-08-04 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
WO2019025545A1
(en)
|
2017-08-04 |
2019-02-07 |
Genmab A/S |
BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
|
|
KR20200052327A
(ko)
|
2017-09-04 |
2020-05-14 |
아게누스 인코포레이티드 |
혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
|
|
US20200216542A1
(en)
|
2017-09-20 |
2020-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
|
JP2020535180A
(ja)
|
2017-09-29 |
2020-12-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療
|
|
BR112020006809A2
(pt)
|
2017-10-06 |
2020-10-06 |
Innate Pharma |
anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso
|
|
KR102823603B1
(ko)
|
2017-10-12 |
2025-06-23 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
면역요법을 위한 t 세포 수용체
|
|
JP7084990B2
(ja)
|
2017-10-13 |
2022-06-15 |
ハープーン セラピューティクス，インク． |
三重特異性タンパク質と使用方法
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
WO2019077062A1
(en)
|
2017-10-18 |
2019-04-25 |
Vivia Biotech, S.L. |
C-CELLS ACTIVATED BY BIT
|
|
KR20200074997A
(ko)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
KR102845789B1
(ko)
|
2017-11-01 |
2025-08-14 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
|
|
CN111601823B
(zh)
|
2017-11-07 |
2024-09-24 |
德克萨斯大学体系董事会 |
用car-t或car-nk细胞在癌症治疗中靶向lilrb4
|
|
EP3710057A1
(en)
|
2017-11-14 |
2020-09-23 |
Pfizer Inc |
Ezh2 inhibitor combination therapies
|
|
JP2021503458A
(ja)
|
2017-11-17 |
2021-02-12 |
ノバルティス アーゲー |
新規のジヒドロイソキサゾール化合物及びｂ型肝炎治療のためのそれらの使用
|
|
MA50900A
(fr)
|
2017-11-17 |
2020-09-23 |
Merck Sharp & Dohme |
Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations
|
|
US20200377571A1
(en)
|
2017-12-08 |
2020-12-03 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
KR102923958B1
(ko)
|
2017-12-15 |
2026-02-06 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
엑소좀 관련 유전자 편집을 이용한 암 치료 방법 및 조성물
|
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
WO2019123285A1
(en)
|
2017-12-20 |
2019-06-27 |
Novartis Ag |
Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
|
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
US20200354424A1
(en)
|
2018-01-26 |
2020-11-12 |
Orionis Biosciences, Inc. |
Xcr1 binding agents and uses thereof
|
|
KR20200128014A
(ko)
|
2018-01-31 |
2020-11-11 |
셀진 코포레이션 |
입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
|
|
JP2021511793A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
|
|
US20200407365A1
(en)
|
2018-02-28 |
2020-12-31 |
Novartis Ag |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
|
EP3765085A1
(en)
|
2018-03-12 |
2021-01-20 |
Université de Paris |
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US12454561B2
(en)
|
2018-03-19 |
2025-10-28 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
WO2019185551A1
(en)
|
2018-03-25 |
2019-10-03 |
Snipr Biome Aps. |
Treating & preventing microbial infections
|
|
WO2019191279A2
(en)
|
2018-03-27 |
2019-10-03 |
Board Of Regents, The University Of Texas System |
Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
|
|
AU2019254237B2
(en)
|
2018-04-16 |
2025-01-30 |
Onquality Pharmaceuticals China Ltd. |
Method for preventing or treating side effects of cancer therapy
|
|
EP3781596A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
US11065317B2
(en)
|
2018-04-26 |
2021-07-20 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
BR112020022294A2
(pt)
|
2018-05-04 |
2021-02-23 |
Tollys |
composição e uso de uma composição
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
CN112165974B
(zh)
|
2018-05-31 |
2024-11-08 |
诺华股份有限公司 |
乙型肝炎抗体
|
|
TW202017569A
(zh)
|
2018-05-31 |
2020-05-16 |
美商佩樂敦治療公司 |
用於抑制cd73之組合物及方法
|
|
CA3102256A1
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Dosing of a bispecific antibody that bind cd123 and cd3
|
|
JP7403479B2
(ja)
|
2018-06-03 |
2023-12-22 |
ランカプ バイオ ベータ リミテッド |
Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体
|
|
CA3103610A1
(en)
|
2018-06-12 |
2019-12-19 |
The Regents Of The University Of California |
Single-chain bispecific chimeric antigen receptors for the treatment of cancer
|
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Ｂｃｍａキメラ抗原受容体及びその使用
|
|
PT3807316T
(pt)
|
2018-06-18 |
2024-07-29 |
Innate Pharma |
Composições e métodos para tratamento de cancro
|
|
AU2019288728A1
(en)
|
2018-06-23 |
2021-01-14 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
BR112021000673A2
(pt)
|
2018-07-18 |
2021-04-20 |
Genentech, Inc. |
métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
AU2019336197A1
(en)
|
2018-09-07 |
2021-02-18 |
Pfizer Inc. |
Anti-avb8 antibodies and compositions and uses thereof
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
WO2020053654A1
(en)
|
2018-09-12 |
2020-03-19 |
Novartis Ag |
Antiviral pyridopyrazinedione compounds
|
|
EP3853251A1
(en)
|
2018-09-19 |
2021-07-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
WO2020069372A1
(en)
|
2018-09-27 |
2020-04-02 |
Elstar Therapeutics, Inc. |
Csf1r/ccr2 multispecific antibodies
|
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
IL305106B2
(en)
|
2018-09-29 |
2025-08-01 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of shp2
|
|
WO2020070053A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
MX2021003765A
(es)
|
2018-10-03 |
2021-07-15 |
Xencor Inc |
Proteínas il-12 de fusión a fc heterodimérico.
|
|
US20210388101A1
(en)
|
2018-10-15 |
2021-12-16 |
Industry-Academic Cooperation Foundation, Yonsei University |
Productivity-enhanced antibody and method for producing same
|
|
JP7467438B2
(ja)
|
2018-10-18 |
2024-04-15 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｒｓｖ抗体の製剤及びその使用方法
|
|
AU2019369299A1
(en)
|
2018-10-29 |
2021-05-20 |
Wisconsin Alumni Research Foundation |
Dendritic polymers complexed with immune checkpoint inhibitors for enhanced cancer immunotherapy
|
|
US11564995B2
(en)
|
2018-10-29 |
2023-01-31 |
Wisconsin Alumni Research Foundation |
Peptide-nanoparticle conjugates
|
|
CN113015748B
(zh)
|
2018-10-31 |
2025-12-12 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
CA3116413A1
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
|
MX2021005024A
(es)
|
2018-11-01 |
2021-07-21 |
Juno Therapeutics Inc |
Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
|
|
CN113316458B
(zh)
|
2018-11-07 |
2024-08-02 |
默沙东有限责任公司 |
抗lag3抗体和抗pd-1抗体的共制剂
|
|
CA3118892A1
(en)
|
2018-11-08 |
2020-05-14 |
Orionis Biosciences, Inc. |
Modulation of dendritic cell lineages
|
|
SG11202105084VA
(en)
|
2018-11-16 |
2021-06-29 |
Juno Therapeutics Inc |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
|
JP7630832B2
(ja)
|
2018-11-19 |
2025-02-18 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
Ｃａｒおよびｔｃｒ形質導入用のモジュール式ポリシストロニックベクター
|
|
EP3947715A4
(en)
|
2018-11-21 |
2022-11-23 |
Board of Regents, The University of Texas System |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
|
|
BR112021010297A2
(pt)
|
2018-11-28 |
2021-08-24 |
Board Of Regents, The University Of Texas System |
Edição de genomas multiplexadores de células imunes para aumentar a funcionalidade e resistência ao ambiente supressivo
|
|
US20220018828A1
(en)
|
2018-11-28 |
2022-01-20 |
Inserm (Institut National De La Santé Et La Recherche Médicale |
Methods and kit for assaying lytic potential of immune effector cells
|
|
WO2020112493A1
(en)
|
2018-11-29 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
|
FI3886875T3
(fi)
|
2018-11-30 |
2024-07-23 |
Juno Therapeutics Inc |
Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
|
|
EP3891270A1
(en)
|
2018-12-07 |
2021-10-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
CN113195467A
(zh)
|
2018-12-11 |
2021-07-30 |
施万生物制药研发Ip有限责任公司 |
适用作alk5抑制剂的萘啶和喹啉衍生物
|
|
US20220047556A1
(en)
|
2018-12-17 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
|
MX2021007392A
(es)
|
2018-12-20 |
2021-08-24 |
Novartis Ag |
Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
|
CN113438961A
(zh)
|
2018-12-20 |
2021-09-24 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
|
|
MX2021007271A
(es)
|
2018-12-21 |
2021-07-15 |
Onxeo |
Nuevas moleculas de acido nucleico conjugado y sus usos.
|
|
KR20240052881A
(ko)
|
2018-12-21 |
2024-04-23 |
노파르티스 아게 |
Pmel17에 대한 항체 및 이의 접합체
|
|
SG11202107606VA
(en)
|
2019-01-15 |
2021-08-30 |
Inst Nat Sante Rech Med |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
|
|
TWI894135B
(zh)
|
2019-01-25 |
2025-08-21 |
德商百靈佳殷格翰國際股份有限公司 |
編碼ccl21之重組棒狀病毒
|
|
CN113365660A
(zh)
|
2019-01-29 |
2021-09-07 |
朱诺治疗学股份有限公司 |
对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
|
|
KR20210126078A
(ko)
|
2019-02-13 |
2021-10-19 |
더 브리검 앤드 우먼즈 하스피털, 인크. |
항-말초 림프절 어드레신 항체 및 그의 용도
|
|
WO2020165834A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
BR112021015783A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
EP3927744A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
US20220184121A1
(en)
|
2019-03-18 |
2022-06-16 |
The Regents Of The University Of California |
Augmentation of t-cell activation by oscillatory forces and engineered antigen-presenting cells
|
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
WO2020208060A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
EP3956446A1
(en)
|
2019-04-17 |
2022-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
MX2021012692A
(es)
|
2019-04-19 |
2021-11-12 |
Genentech Inc |
Anticuerpos anti-mertk y sus metodos de uso.
|
|
MX2021012769A
(es)
|
2019-04-23 |
2021-11-18 |
Innate Pharma |
Anticuerpos bloqueadores cd73.
|
|
CA3138348A1
(en)
|
2019-05-09 |
2020-11-12 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
|
EP3969040A1
(en)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
|
|
EP3968971A1
(en)
|
2019-05-17 |
2022-03-23 |
Cancer Prevention Pharmaceuticals, Inc. |
Methods for treating familial adenomatous polyposis
|
|
CA3144533A1
(en)
|
2019-06-03 |
2020-12-10 |
The University Of Chicago |
Methods and compositions for treating cancer with cancer-targeted adjuvants
|
|
AU2020289485A1
(en)
|
2019-06-03 |
2022-02-03 |
The University Of Chicago |
Methods and compositions for treating cancer with collagen binding drug carriers
|
|
EP3986454A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
US20220349890A1
(en)
*
|
2019-06-18 |
2022-11-03 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
A method for predicting risk of recurrence for early-stage colon cancer by measuring focal adhesion kinase
|
|
CA3143634A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
US12098212B2
(en)
|
2019-08-12 |
2024-09-24 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
|
WO2021042066A1
(en)
|
2019-08-30 |
2021-03-04 |
Foundation Medicine, Inc. |
Kmt2a-maml2 fusion molecules and uses thereof
|
|
AU2020335928A1
(en)
|
2019-08-30 |
2022-02-17 |
Agenus Inc. |
Anti-CD96 antibodies and methods of use thereof
|
|
BR112022004995A2
(pt)
|
2019-09-18 |
2022-06-21 |
Lamkap Bio Alpha AG |
Anticorpos biespecíficos contra ceacam5 e cd3
|
|
CR20220107A
(es)
|
2019-09-18 |
2022-04-25 |
Novartis Ag |
Proteínas de fusión nkg2d y sus usos
|
|
CN114667285B
(zh)
|
2019-09-26 |
2025-08-08 |
诺华股份有限公司 |
抗病毒吡唑并吡啶酮化合物
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
EP4037700A2
(en)
|
2019-10-03 |
2022-08-10 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US20220380765A1
(en)
|
2019-11-02 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
|
TWI895295B
(zh)
|
2019-11-12 |
2025-09-01 |
美商方得生醫療公司 |
偵測編碼新生抗原之融合基因之方法
|
|
EP4061809A1
(en)
|
2019-11-22 |
2022-09-28 |
Theravance Biopharma R&D IP, LLC |
Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
JP2023504568A
(ja)
|
2019-12-04 |
2023-02-03 |
オルナ セラピューティクス インコーポレイテッド |
環状ｒｎａ組成物及び方法
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
US11396647B2
(en)
|
2020-01-07 |
2022-07-26 |
Board Of Regents, The University Of Texas System |
Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
|
|
JP2023511439A
(ja)
|
2020-01-28 |
2023-03-17 |
ジェネンテック， インコーポレイテッド |
がんの治療のためのｉｌ１５／ｉｌ１５ｒアルファヘテロ二量体ｆｃ融合タンパク質
|
|
EP4096789A4
(en)
|
2020-01-29 |
2023-10-11 |
Board of Regents, The University of Texas System |
USE OF POZIOTINIB TO TREAT CANCER WITH NRG1 FUSIONS
|
|
CN115362270A
(zh)
|
2020-01-29 |
2022-11-18 |
得克萨斯州大学系统董事会 |
Egfr/her2酪氨酸激酶抑制剂和/或her2/her3抗体在具有nrg1融合的癌症的治疗中的用途
|
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
IL295896A
(en)
|
2020-02-26 |
2022-10-01 |
Biograph 55 Inc |
c19 c38 bispecific antibodies
|
|
WO2021171264A1
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
Dosing of a bispecific antibody that binds cd123 and cd3
|
|
WO2021176330A1
(en)
|
2020-03-03 |
2021-09-10 |
Array Biopharma Inc. |
Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
|
|
JP2023518295A
(ja)
|
2020-03-20 |
2023-04-28 |
オルナ セラピューティクス インコーポレイテッド |
環状ｒｎａ組成物及び方法
|
|
WO2021191870A1
(en)
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
EP4126824A1
(en)
|
2020-03-31 |
2023-02-08 |
Theravance Biopharma R&D IP, LLC |
Substituted pyrimidines and methods of use
|
|
BR112022020333A2
(pt)
|
2020-04-10 |
2022-11-22 |
Juno Therapeutics Inc |
Métodos e usos relacionados à terapia celular projetada com um receptor de antígeno quimérico que alveja o antígeno de maturação de células b
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
EP4153316A1
(en)
|
2020-05-19 |
2023-03-29 |
Boehringer Ingelheim International GmbH |
Binding molecules for the treatment of cancer
|
|
TW202208418A
(zh)
|
2020-05-21 |
2022-03-01 |
美國德州系統大學評議委員會 |
具有vgll1特異性之t細胞受體及其用途
|
|
MX2022014943A
(es)
|
2020-05-26 |
2023-03-08 |
Inst Nat Sante Rech Med |
Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
|
|
JP7565384B2
(ja)
|
2020-06-03 |
2024-10-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ＣＤ８０細胞外ドメインＦｃ融合タンパク質をコードするリコンビナントラブドウイルス
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
US20210387983A1
(en)
|
2020-06-10 |
2021-12-16 |
Theravance Biopharma R&D Ip, Llc |
Crystalline alk5 inhibitors and uses thereof
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
JP2023531537A
(ja)
|
2020-06-30 |
2023-07-24 |
メンドゥス・ベスローテン・フェンノートシャップ |
卵巣癌ワクチンでの白血病由来細胞の使用
|
|
US20250262293A1
(en)
|
2020-07-07 |
2025-08-21 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer
|
|
JP7819176B2
(ja)
|
2020-08-03 |
2026-02-24 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
IL300328A
(en)
|
2020-08-26 |
2023-04-01 |
Regeneron Pharma |
Methods for treating cancer by administering a PD-1 inhibitor
|
|
JP2023540248A
(ja)
|
2020-08-26 |
2023-09-22 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法
|
|
CA3188236A1
(en)
|
2020-09-14 |
2022-03-17 |
Boehringer Ingelheim International Gmbh |
Heterologous prime boost vaccine
|
|
WO2022084210A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
|
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
|
MX2023005192A
(es)
|
2020-11-04 |
2023-05-15 |
Heidelberg Pharma Res Gmbh |
Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer.
|
|
EP4240377A4
(en)
|
2020-11-05 |
2025-01-15 |
Board of Regents, The University of Texas System |
Engineered t cell receptors targeting egfr antigens and methods of use
|
|
CA3200878A1
(en)
|
2020-11-12 |
2022-05-19 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
|
|
CA3201499A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
|
CA3204091A1
(en)
|
2020-12-08 |
2022-06-16 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
|
RS65211B1
(sr)
|
2020-12-18 |
2024-03-29 |
Lamkap Bio Beta Ag |
Bispecifična antitela protiv ceacam5 i cd47
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022159492A1
(en)
|
2021-01-19 |
2022-07-28 |
William Marsh Rice University |
Bone-specific delivery of polypeptides
|
|
EP4281102A1
(en)
|
2021-01-22 |
2023-11-29 |
Mendus B.V. |
Methods of tumor vaccination
|
|
CA3210196A1
(en)
|
2021-01-29 |
2022-08-04 |
Board Of Regents, The University Of Texas System |
Methods of treating cancer with kinase inhibitors
|
|
CN117222413A
(zh)
|
2021-02-10 |
2023-12-12 |
同润生物医药(上海)有限公司 |
治疗肿瘤的方法和组合
|
|
EP4301784A4
(en)
*
|
2021-03-02 |
2025-01-01 |
NovaRock Biotherapeutics, Ltd. |
Antibodies against claudin-6 and uses thereof
|
|
JP2024510947A
(ja)
|
2021-03-05 |
2024-03-12 |
レアダルティス、ソシエダッド リミターダ |
三量体ポリペプチドおよびがん治療におけるその使用
|
|
CA3212351A1
(en)
|
2021-03-12 |
2022-09-15 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
|
WO2022194988A2
(en)
|
2021-03-19 |
2022-09-22 |
Heidelberg Pharma Research Gmbh |
B-lymphocyte specific amatoxin antibody conjugates
|
|
MX2023011007A
(es)
|
2021-03-23 |
2023-12-07 |
Regeneron Pharma |
Metodos para tratar el cancer en pacientes inmunosuprimidos o inmunocomprometidos mediante la administracion de un inhibidor de pd-1.
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
|
AU2022254104A1
(en)
|
2021-04-08 |
2023-10-26 |
Nurix Therapeutics, Inc. |
Combination therapies with cbl-b inhibitor compounds
|
|
WO2022216979A1
(en)
|
2021-04-08 |
2022-10-13 |
Board Of Regents, The University Of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
US20240239895A1
(en)
|
2021-04-09 |
2024-07-18 |
Genentech, Inc. |
Combination therapy with a raf inhibitor and a pd-1 axis inhibitor
|
|
US20240228659A1
(en)
|
2021-04-14 |
2024-07-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
|
CA3216880A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
CN117396222A
(zh)
|
2021-05-21 |
2024-01-12 |
天津立博美华基因科技有限责任公司 |
药物组合及其用途
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
WO2022254337A1
(en)
|
2021-06-01 |
2022-12-08 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
EP4367269A1
(en)
|
2021-07-05 |
2024-05-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
MX2024000674A
(es)
|
2021-07-13 |
2024-02-07 |
BioNTech SE |
Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
|
|
WO2023015198A1
(en)
|
2021-08-04 |
2023-02-09 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
|
|
IL310550A
(en)
|
2021-08-04 |
2024-03-01 |
Univ Colorado Regents |
LAT-activating chimeric antigen receptor T cells and methods of using them
|
|
CA3231180A1
(en)
|
2021-09-08 |
2023-03-16 |
Redona Therapeutics, Inc. |
Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
|
|
WO2023056361A1
(en)
|
2021-09-29 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Anti-hsp70 antibodies and therapeutic uses thereof
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
IL311790A
(en)
|
2021-10-05 |
2024-05-01 |
Chang Hao Ming |
Natural killer cells and methods of use thereof
|
|
US20250002600A1
(en)
|
2021-10-06 |
2025-01-02 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination therapy
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
TW202330612A
(zh)
|
2021-10-20 |
2023-08-01 |
日商武田藥品工業股份有限公司 |
靶向ｂｃｍａ之組合物及其使用方法
|
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
CN118765283A
(zh)
|
2021-11-17 |
2024-10-11 |
国家健康科学研究所 |
通用沙贝病毒疫苗
|
|
US20240294926A1
(en)
|
2021-12-16 |
2024-09-05 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
WO2023129438A1
(en)
|
2021-12-28 |
2023-07-06 |
Wisconsin Alumni Research Foundation |
Hydrogel compositions for use for depletion of tumor associated macrophages
|
|
WO2023142996A1
(zh)
|
2022-01-28 |
2023-08-03 |
上海岸阔医药科技有限公司 |
预防或治疗与抗肿瘤剂相关的疾病或病症的方法
|
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
|
TWI864587B
(zh)
|
2022-02-14 |
2024-12-01 |
美商基利科學股份有限公司 |
抗病毒吡唑并吡啶酮化合物
|
|
CA3243885A1
(en)
|
2022-02-17 |
2023-08-24 |
Vyriad, Inc. |
COMBINATIONS OF CHECKPOINT INHIBITORS AND ONCOLYTIC VIRUS FOR CANCER TREATMENT
|
|
KR20240150493A
(ko)
|
2022-02-21 |
2024-10-15 |
온퀄리티 파마슈티컬스 차이나 리미티드 |
화합물 및 그 용도
|
|
JP2025515324A
(ja)
|
2022-04-28 |
2025-05-14 |
エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント |
がんを処置するためのキメラ抗原受容体改変調節性ｔ細胞
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
AU2023269545A1
(en)
|
2022-05-12 |
2024-11-14 |
BioNTech SE |
Binding agents capable of binding to cd27 in combination therapy
|
|
KR20250025384A
(ko)
|
2022-06-16 |
2025-02-21 |
람카프 바이오 베타 엘티디. |
Ceacam5 및 cd47에 대한 이중특이적 항체 및 ceacam5 및 cd3에 대한 이중특이적 항체의 조합 요법
|
|
US20250381272A1
(en)
|
2022-06-22 |
2025-12-18 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
|
KR20250047766A
(ko)
|
2022-08-05 |
2025-04-04 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Gprc5d 및 bcma에 특이적인 키메라 항원 수용체
|
|
EP4583860A1
(en)
|
2022-09-06 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
KR20250099224A
(ko)
|
2022-11-01 |
2025-07-01 |
하이델베르크 파마 리서치 게엠베하 |
항-gucy2c 항체 및 이의 용도
|
|
EP4626446A1
(en)
|
2022-12-01 |
2025-10-08 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
|
CN120712102A
(zh)
|
2022-12-13 |
2025-09-26 |
朱诺治疗学股份有限公司 |
对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
|
|
IL321098A
(en)
|
2022-12-14 |
2025-07-01 |
Astellas Pharma Europe Bv |
Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
|
|
CN121002071A
(zh)
|
2023-01-20 |
2025-11-21 |
勃林格殷格翰国际有限公司 |
IL-12 Fc融合蛋白
|
|
EP4658687A1
(en)
|
2023-01-31 |
2025-12-10 |
University of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
EP4680285A1
(en)
|
2023-03-13 |
2026-01-21 |
Heidelberg Pharma Research GmbH |
Subcutaneously administered antibody-drug conjugates for use in cancer treatment
|
|
KR20250155054A
(ko)
|
2023-03-13 |
2025-10-29 |
리제너론 파마슈티칼스 인코포레이티드 |
흑색종 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용
|
|
TW202440636A
(zh)
|
2023-03-21 |
2024-10-16 |
美商傳記５５有限公司 |
Ｃｄ１９／ｃｄ３８多特異性抗體
|
|
WO2024209072A1
(en)
|
2023-04-06 |
2024-10-10 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 for treating cancer
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024213767A1
(en)
|
2023-04-14 |
2024-10-17 |
Institut National de la Santé et de la Recherche Médicale |
Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
|
|
TW202509071A
(zh)
|
2023-05-12 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
能夠與ｏｘ４０結合之抗體、其變異體及其用途
|
|
WO2024261302A1
(en)
|
2023-06-22 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
|
|
WO2025003193A1
(en)
|
2023-06-26 |
2025-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
WO2025050009A2
(en)
|
2023-09-01 |
2025-03-06 |
Children's Hospital Medical Center |
Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
US20250114468A1
(en)
|
2023-10-09 |
2025-04-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
|
|
WO2025106736A2
(en)
|
2023-11-15 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
|
|
TW202540189A
(zh)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
在組合療法中能夠結合ｏｘ４０之抗體
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
TW202541837A
(zh)
|
2023-12-08 |
2025-11-01 |
日商安斯泰來製藥公司 |
含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025132695A1
(en)
|
2023-12-19 |
2025-06-26 |
Boehringer Ingelheim International Gmbh |
Recombinant rhabdovirus encoding for a gasdermin
|
|
WO2025210175A1
(en)
|
2024-04-04 |
2025-10-09 |
Centre National De La Recherche Scientifique |
Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
|
|
WO2025248505A1
(en)
|
2024-05-31 |
2025-12-04 |
Wayne State University |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026012976A1
(en)
|
2024-07-08 |
2026-01-15 |
Institut National de la Santé et de la Recherche Médicale |
Use of inhibitor of gasdermind for treatment of rac2 monogenic disorders
|
|
WO2026037839A2
(en)
|
2024-08-12 |
2026-02-19 |
ONA Therapeutics S.L. |
Anti-fgfr4 molecules and uses thereof
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
WO2026052851A2
(en)
|
2024-09-09 |
2026-03-12 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitor of ciliogenesis for use in a method of preventing therapeutic resistance in cancer
|